4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:50 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $140.1M (164.4% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 7, 2026 | Jan 10, 2025 | Feb 29, 2024 | Mar 15, 2023 | Mar 28, 2022 |
| Revenue | $85.2M | $37.0K | $20.7M | $3.13M | $18.0M |
| Operating expenses | $244.8M | $187.9M | $133.6M | $113.2M | $89.4M |
| Research and development | $195.7M | $141.3M | $97.1M | $80.3M | $61.4M |
| Selling, general and administrative | $49.1M | $46.6M | $36.5M | $32.9M | $28.0M |
| Operating income | -$159.5M | -$187.8M | -$112.9M | -$110.0M | -$71.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$140.1M | -$160.9M | -$100.8M | -$107.5M | -$71.3M |
| EPS, basic | $-2.42 | $-2.98 | $-2.58 | $-3.32 | – |
| EPS, diluted | $-2.42 | $-2.98 | $-2.58 | $-3.32 | – |
| Weighted shares, basic | 57.9M | 53.9M | 39.1M | 32.4M | – |
| Weighted shares, diluted | 57.9M | 53.9M | 39.1M | 32.4M | – |
| Margins and growth | |||||
| Operating margin | -187.2% | -507678.4% | -544.6% | -3516.5% | -395.5% |
| Net margin | -164.4% | -434778.4% | -486.6% | -3435.4% | -395.4% |
| Revenue growth, year over year | +230,194.6% | −99.8% | +562.3% | −82.7% | +32.5% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 7, 2026 | Jan 10, 2025 | Feb 29, 2024 | Mar 15, 2023 | Mar 28, 2022 |
| Cash and equivalents | $60.2M | $149.3M | $249.1M | $52.4M | $153.0M |
| Short-term investments | $342.4M | $275.5M | $39.1M | $161.2M | $94.8M |
| Accounts receivable | – | – | – | $0 | $47.0K |
| Total current assets | $413.1M | $434.9M | $296.6M | $220.5M | $256.3M |
| Property, plant and equipment | $14.9M | $19.5M | $20.1M | $22.3M | $14.4M |
| Total assets | $566.7M | $560.4M | $339.9M | $261.8M | $353.5M |
| Accounts payable | $11.2M | $4.39M | $3.52M | $3.32M | $4.76M |
| Total current liabilities | $44.0M | $29.1M | $19.0M | $15.7M | $16.3M |
| Total liabilities | $61.0M | $49.8M | $32.1M | $30.5M | $34.4M |
| Shareholders' equity | $505.7M | $510.6M | $307.8M | $231.3M | $319.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 7, 2026 | Jan 10, 2025 | Feb 29, 2024 | Mar 15, 2023 | Mar 28, 2022 |
| Operating cash flow | -$109.1M | -$134.6M | -$75.8M | -$86.7M | -$69.1M |
| Capital expenditures | $536.0K | $3.79M | $2.77M | $11.5M | $9.11M |
| Free cash flow | -$109.6M | -$138.4M | -$78.6M | -$98.2M | -$78.2M |
| Depreciation and amortization | $4.69M | $4.65M | $4.20M | $2.40M | $1.52M |
| Stock-based compensation | $22.0M | $26.1M | $19.7M | $17.1M | $13.8M |
| Investing cash flow | -$93.0M | -$302.4M | $115.7M | -$17.1M | -$172.7M |
| Financing cash flow | $113.0M | $337.3M | $156.8M | $3.08M | $118.1M |
| Net change in cash | -$89.1M | -$99.8M | $196.8M | -$100.7M | -$123.7M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 25.8% | 70583.8% | 94.9% | 547.2% | 76.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Feb 23, 2024 | 49.8M | +49.8% | SEC |
| Nov 2, 2023 | 42.8M | +32.0% | SEC |
| Aug 4, 2023 | 42.1M | +29.9% | SEC |
| May 5, 2023 | 33.3M | +3.0% | SEC |
| Mar 8, 2023 | 33.2M | +3.1% | SEC |
| Nov 2, 2022 | 32.4M | +0.8% | SEC |
| Aug 8, 2022 | 32.4M | +20.0% | SEC |
| May 12, 2022 | 32.3M | +20.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.